IGF1 potentiates the pro-inflammatory response in human peripheral blood mononuclear cells via MAPK

Thalijn Liliana Catharina Wolters, Mihai Gheorghe Netea, Adrianus Rudolfus Marinus Maria Hermus, Johannes Willem Adriaan Smit and Romana Teodora Netea-Maier
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Abstract

Acromegaly is characterized by growth hormone (GH) and insulin-like growth factor 1 (IGF1) excess and is accompanied by an increased cardiovascular diseases (CVD) risk. As innate immune responses are crucial in CVD development, and IGF1 is linked to subclinical inflammation, we hypothesized that GH/IGF1 excess contributes to CVD development by potentiating systemic inflammation. We aimed to assess the effects of GH/IGF1 on inflammatory cytokine production. Whole blood from acromegaly patients and healthy volunteers and peripheral blood mononuclear cells (PBMCs) from healthy volunteers were stimulated with Toll-like receptor (TLR) ligands, with or without adding GH or IGF1 (in PBMC). Cytokine concentrations were measured by ELISA. The underlying signalling pathways were investigated by the inhibition of downstream targets of the IGF1 receptor. The following results were obtained. GH or IGF1 alone did not influence cytokine production in PBMCs. GH did not affect TLR-induced cytokine production, but co-stimulation with IGF1 dose dependently increased the TLR ligand-induced production of IL6 (P<0.01), TNF alpha (P=0.02) and IFNg (P<0.01), as well as the production of the anti-inflammatory cytokine IL10 (P=0.01). IGF1 had no effect on IL1B, IL17 and IL22 production. Inhibition of the MAPK pathway, but not mTOR, completely abrogated the synergistic effect of IGF1 on the LPS-induced IL6 and TNF alpha production. In whole blood of acromegaly patients, ex vivo IL6 production was increased (P<0.01). In conclusion, IGF1, but not GH, has pro-inflammatory effects, probably via the MAPK signalling pathway and might be involved in the pathogenesis of atherosclerosis in acromegaly. The increased IL10 production possibly counteracts the pro-inflammatory effects.

Introduction

Acromegaly is an endocrine disease characterized by overproduction of growth hormone (GH), which is in the majority of cases caused by a GH-producing pituitary adenoma. GH stimulates the endogenous production of insulin-like growth factor 1 (IGF1), primarily by the liver, but also (in much lower amounts) in almost every other cell, including immune cells (Kooijman et al. 1992). Most patients with acromegaly are exposed to excessive levels...
of GH and IGF1 for many years. They are also known to have an increased risk of developing atherosclerosis and CVD (Dekkers et al. 2008).

In the last decades, abundant evidence has become available on the crucial role of inflammation in the pathogenesis of atherosclerosis (Hansson & Libby 2006). Interestingly, Touskova and coworkers (Touskova et al. 2012) recently suggested a regulatory role of IGF1 in the development of subclinical inflammation through the pro-inflammatory activation of peripheral monocytes. IGF1 has been suggested to modulate the human immune response (Weigent 2013, Higashi et al. 2014) and a pro-inflammatory state with higher concentrations of TNF alpha and IL8 is present in acromegaly (Arikan et al. 2009). Moreover, a recent study found positive correlations between IGF1 levels and two markers of inflammation: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (Ucler et al. 2015).

Based on these findings, it may be hypothesized that prolonged exposure of immune cells to increased GH and IGF1 levels induces a pro-inflammatory state that contributes to the development of cardiovascular diseases (CVD) in acromegaly. Few studies have assessed the direct effects of GH and/or IGF1 on cytokine production (Renier et al. 1996, Kooijman & Coppens 2004). The immune-modulating effects of IGF1 have been described in various types of immune cells, mainly in lymphocytes (Imperlini et al. 2015) and monocytes (Renier et al. 1996), with both pro- and anti-inflammatory effects being reported (Higashi et al. 2014): the final effect depends on the administered dose of IGF1, the nature of the (co) stimulus and the type of immune cell involved. However, the majority of these studies were performed before the discovery of activation of inflammation by pathogen recognition receptors, such as Toll-like receptors (TLRs) (Akira 2001), and before the role of T-helper cell (Th) subsets in atherosclerosis (Robertson & Hansson 2006) was elucidated. Therefore, the exact mechanisms by which GH and/or IGF1 could influence inflammatory cells are not completely understood.

The hypothesis of this study is that supra-physiological levels of IGF1 have pro-inflammatory effects on circulating immune cells, which may contribute to the well-known increased risk of CVD and insulin resistance in acromegaly patients (Che et al. 2002, Ucler et al. 2015). In this study, we aimed to comprehensively assess the effects of GH and IGF1 on TLR ligand-induced cytokine production in immune cells. We therefore set out to assess both monocyte-derived and Th-derived cytokine production and the signalling pathways that are involved in these processes.
Materials and methods

Reagents and microorganisms

TLR2 ligand Pam3Cys was purchased from InvivoGen (San Diego, CA, USA) and used in a concentration 10ng/mL. E. coli LPS (serotype 055:B5) was purchased from Sigma-Aldrich, repurified as previously described and used as an ultrapure TLR4 ligand (Hirschfeld et al. 2001) in a concentration of 1 ng/mL for peripheral blood mononuclear cells (PBMCs) and 100 ng/mL for whole blood (WB). For the stimulation of Th cells, Candida albicans ATCC MYA-3573 (UC 820), a strain well described elsewhere (Lehrer & Cline 1969), was used. C. albicans was grown overnight in Sabouraud broth at 37°C, whereafter cells were harvested by centrifugation, washed twice and resuspended in Roswell Park Memorial Institute (RPMI) 1640 culture medium (Dutch Modification, Gibco, Thermo Scientific) (van der Graaf et al. 2005). C. albicans yeasts were heat-killed for 30min at 95°C; all stimulations with C. albicans conidia were with a concentration of 10⁶/mL. All mentioned concentrations are the final concentrations that are present in the well.

Figure 2

Effects of IGF1 on the ex vivo monocyte-derived cytokine production in PBMCs from healthy volunteers (n = 12). (A) TNF alpha, (B) IL6, (C) IL1B and (D) IL10. Cytokine levels are displayed in pg/mL. Analyses were performed using the Wilcoxon matched-pairs signed-rank test. *P values <0.05 are considered statistically significant. *P<0.05; **P<0.01. IGF1, insulin-like growth factor 1; IL, interleukin; LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cell; P3C, Pam3Cys; RPMI, Roswell Park Memorial Institute (medium); TNF alpha, tumour necrosis factor alpha.
Inflammatory effects of IGF1

PBMC, peripheral blood mononuclear cell; RPMI, Roswell Park Memorial Institute (medium).

PBMCs from healthy volunteers (n=8). Cytokine levels are displayed in pg/mL. Analyses were performed using the Wilcoxon matched-pairs signed-rank test. *P <0.05; **P <0.01. C. albicans, Candida albicans heat-killed conidia; IFNg, interferon gamma; IGF1, insulin-like growth factor 1; IL, interleukin; *P values <0.05 are considered statistically significant.

Subjects

Human PBMCs were obtained from buffy coats of healthy blood donors (Sanquin Blood bank, Amsterdam, The Netherlands). Whole blood (WB) was obtained from healthy volunteers (n=24; 10 males, 14 females) and from consecutive patients with active acromegaly (n=12; 7 males, 5 females), who visited the outpatient clinic of the division of Endocrinology in the Radboud University Medical Center Nijmegen, the Netherlands. All patients had a biochemically confirmed diagnosis of acromegaly and elevated IGF1 levels (≥2.4–19.6 s.d.; corrected for sex and age) upon participation. Exclusion criteria included use of statins or other anti-inflammatory drugs and presence of active infectious or inflammatory diseases or malignancies. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics committee of our institution (CMO 2010/104; CMO 2012/131). All participants signed informed consent prior to participation in this study.

In vitro stimulation of human PBMCs

Separation and stimulation of PBMCs was performed as described previously (Endres et al. 1988, Netea et al. 2006). In short, the PBMC fraction was obtained by density centrifugation of diluted blood (one part blood to one part pyrogen-free saline) over Ficoll-Paque (GE Healthcare). Cells were washed twice in saline and suspended in RPMI-1640 culture medium supplemented with gentamicin 0.105 mmol/L (Centrafarm, Etten-Leur, The Netherlands), Glutamax 2 mmol/L (Gibco, Thermo Scientific) and pyruvate 1 mmol/L (Gibco, Thermo Scientific). The cells were counted in a Coulter counter, and their number was adjusted to 5 × 10^6 cells/mL. Five hundred thousand PBMCs in a volume 100 μL were incubated at 37°C in round-bottom 96-well plates (Greiner; Kremsmünster, Austria) with a total added volume of 100 μL of stimulus (TLR ligand, GH or IGF1) or RPMI (negative control) per well. GH (R&D systems) was used in concentrations of 0.6, 6, 60 and 600 ng/mL (2.73 × 10⁻², 2.73 × 10⁻¹, 2.73 and 27.3 pmol/mL) and IGF1 (R&D Systems) was used in concentrations of 0.05, 0.5 and 5 μg/mL (6.536, 65.36 and 653.6 nmol/L). In separate experiments, aimed to assess the effects of different signalling pathways, Five hundred thousand PBMCs in a volume 50 μL were preincubated for 30 min with either 50 μL of the mTOR-inhibitor rapamycin 0.1 μmol/L (R0395; Sigma-Aldrich) or the MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK)-inhibitor U0126 10 μmol/L (Promega) or dimethyl sulfoxide (DMSO; Cryosure-DMSO >99.9% USP grade, WAK-Chemie Medical GmbH, Steinbach/Ts., Germany) as a negative control before stimulation with 50 μL of either a LPS 1 ng/mL or RPMI (negative control) and either 50 μL of IGF1 (5 μg/mL) or RPMI (negative control). After 24 h of incubation, supernatants were collected and stored at −20°C until assayed.

Ex vivo stimulation of WB

Venous blood was drawn in 4 mL lithium-heparin tubes (Vacutainer, BD; Franklin Lakes, NJ, USA). 100 μL of WB was incubated at 37°C in 48-well plates (Greiner) with 400 μL of stimulus (LPS 100 ng/mL or C. albicans 106/mL or RPMI (negative control) per well (van Crevel et al. 1999). After 24 h of incubation, supernatants were collected and stored at −20°C until assayed.

Determination of cytokine levels

Human cytokine concentrations were measured by commercial enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s instructions: tumour necrosis factor alpha (TNF alpha), interleukin 1 beta (IL1B), interleukin 17 (IL17), interleukin 22 (IL22) (DuoSet ELISA, R&D Systems), interleukin 10 (IL10), interleukin 6 (IL6), interferon gamma (IFNg) (PeliKine Compact, Sanquin;
Amsterdam). The sensitivity of the assays was 1.5 pg/mL for IL6, 2.34 pg/mL for IL10, 3.9 pg/mL for IL1B and IFNg, 7.8 pg/mL for TNF alpha and 15.6 pg/mL for IL22.

**Western blots**

For Western blotting of ERK (total and phosphorylated), 2.5 × 10⁶ PBMCs were incubated with either a MEK inhibitor or RPMI in polypropylene tubes for 30 min at 37°C. Subsequently, LPS (1 ng/mL) or RPMI was added, followed by IGF1 (5 µg/mL) or RPMI, and cells were incubated at 37°C. After 1 h, cells were lysed in 100 µL of lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 10% glycerol (v/v), 1% Triton X-100 (v/v), 40 mM b-glycerophosphate, 50 mM sodium fluoride, 200 mM sodium orthovanadate, complete mini EDTA-free protease inhibitor cocktail and PhosSTOP Phosphatase Inhibitor Cocktail (Roche)). Protein concentration was determined by a BCA assay (Pierce BCA assay; Thermo Scientific). Equal amounts of protein were subjected to SDS-PAGE electrophoresis using 4–15% precast polyacrylamide gels (Mini-protean TGX, Bio-Rad). Primary antibodies (1:1000) in 5% (w/v) bovine serum albumin (BSA)/TBST (Tris-buffered saline, Tween 20) were incubated overnight at 4°C. HRP-conjugated anti-rabbit antibody at a dilution of 1:5000 in 5% (w/v) milk/TBST was used for 1 h at room temperature. Quantitative assessment of band intensity was performed by Image Lab statistical software (Bio-Rad). The following
antibodies were used: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (Cell Signalling, #9101) and p44/42 MAPK (Erk1/2) antibody (Cell Signalling, #9102).

Statistical analysis
The differences between experimental groups were analysed using the Wilcoxon matched-pairs signed-rank test for PBMC data, and the Mann–Whitney U test for WB data (unless otherwise stated). Statistical analyses were performed with Prism software (version 5.03; GraphPad), which was also used to produce the graphs. Western blots were analysed and quantified using Image Lab 5.0 (build 18 (2013), Bio-Rad). The level of significance was defined as a P value of <0.05. Cytokine production in PBMC is plotted as bar charts and cytokine production in WB as dots, both with mean±S.E.M. All stimulation experiments were performed at least three times, with a minimum of six volunteers. The Western blot experiments were performed in duplicate.

Results

Effects of GH on cytokine production
In our research model, stimulation of PBMCs with different concentrations of GH did not induce monocyte-derived (TNF alpha, IL6, IL1B) or Th-derived (IFNg, IL17, IL22) pro-inflammatory cytokine production, nor did it induce the production of the anti-inflammatory cytokine IL10. In addition, in PBMCs stimulated with various TLR-agonists or microorganisms (LPS, Pam3Cys, C. albicans), co-stimulation with GH did not influence cytokine production (Fig. 1).

Effects of IGF1 on cytokine production
Stimulation with IGF1 alone did not induce inflammatory cytokine production in PBMCs (data not shown). However, IGF1 potentiated LPS-induced TNF alpha production (Fig. 2A) and LPS-induced and Pam3Cys-induced IL6 production (Fig. 2B) in PBMCs obtained from healthy volunteers. IGF1 did not significantly affect the TLR-induced IL1B production (Fig. 2C). In Th, IGF1 potentiated C. albicans-induced IFNg production, but had no effect on IL17 and IL22 production (Fig. 3). In addition, IGF1 stimulation led to a significant increase in the TLR-induced production of the anti-inflammatory cytokine IL10 (Fig. 2D). These effects are dose dependent, since cytokine production increases with higher doses of IGF1 (Fig. 4).

IL-6 production in WB from acromegaly patients
In WB obtained from acromegaly patients, an increased IL6 production on stimulation with LPS (Fig. 5A) and C. albicans (Fig. 5B) was observed, compared to healthy controls.
Signalling mechanisms involved in the effects of IGF1 on cytokine production.

To further investigate the mechanisms through which IGF1 influences cytokine production, specific intracellular signalling pathways were inhibited. First, the mTOR-inhibitor rapamycin was used to investigate the PI3K-Akt-mTOR pathway, which is known to be an important intracellular pathway induced by IGF1 and which is also known to modulate cytokine production in monocytes and T-helper cells. Pre-incubation with rapamycin did not affect TNF alpha (Fig. 6A) production or IL6 production (Fig. 6B) in PBMC stimulated with LPS and IGF1. Second, the MEK-inhibitor U0126 was used to investigate the role of the MAPK pathway, another important intracellular signalling pathway for the stimulation of cytokine production. Indeed, inhibition of MAPK pathway by U0126 completely abrogated the synergistic effect of IGF1 on the TNF alpha (Fig. 7A) and IL6 (Fig. 7B) production induced by LPS, suggesting an important role of this pathway for the effects of IGF1. These findings were confirmed by a reduced expression of phosphorylated ERK1/2 (pERK1/2; Fig. 7B) in PBMCs stimulated with LPS and IGF1, after pre-incubation with U0126. ERK1/2 is a downstream target of MEK, which was inhibited by U0126.

**Discussion**

Patients with acromegaly have an increased risk of atherosclerosis and CVD; low-grade inflammation is hypothesized to play an important role in these diseases. In this study, we report that IGF1, present in high circulating concentrations in patients with active acromegaly, potentiates the microbial TLR ligand-induced inflammatory cytokine production. This observed effect of IGF1 on the production of monocyte-derived pro-inflammatory cytokines is supported by earlier studies (Renier et al. 1996, Tu et al. 1999) and by WB stimulation data from patients with active acromegaly. In contrast, no effects of IGF1 on basal or TLR ligand-induced production of IL1B, IL17 or IL22 were observed. Interestingly, exposure of immune cells to GH did not influence basal or TLR ligand-induced cytokine production. In addition, the MAPK pathway mediates, at least partially, the above-mentioned stimulatory effects of IGF1 on monocyte-derived pro-inflammatory cytokine production. These
findings suggest that IGF1, rather than GH, contributes to the increased inflammatory status and the inflammation-related complications in a state of GH excess.

Interestingly, IGF1 not only influenced monocyte-derived cytokines, but also potentiated the production of IFNg, a T cell-derived pro-inflammatory cytokine. The fact that stimulation with a naturally occurring colonizer such as *C. albicans* increases IFNg production is in line with a previous study that found increased IFNg production in mononuclear cells after stimulation with IGF1 and PHA (Tu et al. 1999).

Besides Th1, other lymphocyte subsets, such as the more recently described Th17, also release important pro-inflammatory cytokines (Park et al. 2005). Th17 produces IL17 and IL22, two important regulatory cytokines for inflammation and atherosclerosis (Liang et al. 2006). In our study, production of these cytokines was not influenced by IGF1. This is in line with our observation that IGF1 stimulation does not affect IL1B production, since IL1B is crucial for the induction of Th17 responses (Dinarello 2011). These data suggest that the effects of IGF1 are not indiscriminate, but rather specific, in targeting certain cytokine responses.

In addition to analysis of pro-inflammatory cytokines, we also assessed the impact of IGF1 on the production of the anti-inflammatory cytokine IL10, which was also potentiated by IGF1 stimulation. This is possibly a counteracting mechanism for some of the pro-inflammatory effects of IGF1 (Spitz et al. 2016).

It is also important to underline that, in agreement with previous reports (Tu et al. 1999, Kooijman et al. 2002, Himpe et al. 2008), IGF1 did not induce cytokine production by itself, while it potentiated cytokine production induced by microbial TLR ligands. This suggests that a combination of ligands is needed to obtain the inflammatory effects of IGF1. The inflammatory effects of IGF1 are very relevant in the context of the metabolic and cardiovascular complications of acromegaly, since TNF alpha, IL6 and IFNg all contribute to the pathophysiology of atherosclerosis in vivo (Hansson & Libby 2006, Hansson et al. 2006, Moss & Ramji 2015, Ridker 2016). In addition, the TLR ligands LPS (part of the outer membrane of Gram negative bacteria in the gut) and *C. albicans* (naturally colonizing yeast) can also be found in the in vivo situation (Raetz & Whitfield 2002, Kumamoto 2011). We chose to stimulate the PBMCs with TLR 2/4 ligands because TLRs represent a major signalling pathway that triggers inflammation; the human body

Figure 7
Effects of inhibition of MAPK (U0126 10μM) signalling pathways on pERK/ERK expression (Western blot) and monocyte-derived cytokine production induced by IGF1 5μg/mL and LPS 1 ng/mL (n=8). (A) TNF alpha, (B) IL6. Cytokine levels are displayed in pg/mL. Analyses were performed using the Wilcoxon matched-pairs signed-rank test. P values <0.05 are considered statistically significant. *P<0.05; **P<0.01. IGF1, insulin-like growth factor 1; IL, interleukin; LPS, lipopolysaccharide; MEK, MAPK/extracellular signal-regulated kinase; pERK, phosphorylated extracellular signal-regulated kinase; RPMI, Roswell Park Memorial Institute (medium); tERK, total ERK; TNF alpha, tumour necrosis factor alpha; U0126, MEK-inhibitor U0126.
contains an abundance of endogenous TLR 2/4 ligands, including degraded extracellular matrix components, extracellular heat shock proteins, high mobility group box 1, oxLDL and extracellular nuclear materials (Kawai & Akira 2010). These ligands are released as a result of cell death or injury. This suggests that TLR signalling is the most likely mediator of inflammation.

Additionally, we investigated the mechanisms through which IGF1 exerts these effects on cytokine production. LPS and P3C signalling in PBMC is mediated though TLR4 and TLR2, respectively, which are both important receptors in the pathogenesis of atherosclerosis (Moghimpour Bijani et al. 2012). TLRs induce downstream signalling pathways including PI3K/Akt/mTOR and MAPK, which are reported to induce cytokine production via NFκB signalling (Takeda et al. 2003, Luyendyk et al. 2008). The IGF1 receptor shares these downstream targets with TLRs (Taniguchi et al. 2006, Youngren 2007).

However, in our model, inhibition of the Akt/mTOR pathway by rapamycin did not influence the effects of IGF1 significantly, suggesting that a different pathway is involved. MAPK signalling is reported to mediate both IGF-initiated responses and TNF alpha/IL6 production in PBMCs (Liu et al. 2003, Olness et al. 2011), whereby activation of MAPK increases pro-inflammatory cytokine production. In line with this, both LPS-induced and LPS/IGF1-induced cytokine production and pERK expression were significantly attenuated by a MEK inhibitor. However, the reduction in cytokine production and pERK expression was more pronounced after co-stimulation with IGF1 and LPS compared to LPS. This suggests that the synergistic effects of IGF1 on TLR stimulation are, at least partially, mediated through MAPK signalling. The MAPK signalling pathway is also an important pathway in the development of atherosclerosis (Muslin 2008).

In contrast to IGF1, stimulation of PBMCs with GH neither influences basal nor TLR ligand-induced cytokine production in PBMCs from healthy donors. While this is supported by some earlier research (Zarkesh-Esfahani et al. 2000), others reported that GH increased the production of IFNg and IL1B in murine peritoneal macrophages (Sodhi & Tripathi 2008). Haeffner and coworkers report an inhibitory effect on TNF alpha secretion in monocytes and macrophages stimulated with both GH and LPS (Haeffner et al. 1997). Differences in the experimental models, as well as differences between species (humans in our study vs mice in other reports) are likely to account for these differences.

Our ex vivo model is characterized by a relatively short exposition to GH or IGF1, which does not fully resemble the in vivo situation. Since acromegaly is characterized by a chronic GH and IGF1 excess, we validated our results in PBMC by analysing the cytokine production in stimulated WB obtained from patients with active acromegaly and healthy controls. The IL6 production in WB from acromegaly patients was increased compared to controls. To further validate these findings, stimulation of PBMC obtained from acromegaly patients is needed and to separate the effects of GH and IGF1, combined ex vivo stimulation with GH and IGF1 is necessary. Future studies should also use endogenous ligands that are involved in the pathophysiology of inflammatory diseases, such as oxidized LDL, palmitate (Haversen et al. 2009) or heat shock proteins (Steinberg & Witztum 2010, Tamura et al. 2012). Furthermore, a more comprehensive analysis on the activation of molecular pathways that are involved in GH/IGF1 signalling and inflammation will provide additional information about the underlying mechanisms.

In conclusion, IGF1, but not GH, has important potentiating effects on the production of specific pro-inflammatory cytokines in PBMC ex vivo. In addition, stimulation of WB from acromegaly patients results in a more pronounced increase in IL6 production compared to controls. Our data suggest that IGF1 excess induces pro-inflammatory cytokine production in circulating immune cells, and thereby potentiates the effect of endogenous TLR ligands. This effect is suggested to be mediated via the MAPK pathway and can possibly explain the increased cardiovascular risks in acromegaly. Therefore, targeting both IGF1 overproduction and systemic inflammation seems a possible future approach to reduce cardiovascular morbidity in acromegaly. Further research is needed to elucidate the mechanisms and consequences of GH/IGF1 excess, both ex vivo as in vivo.
References

Akira S 2001 Toll-like receptors and innate immunity. Advances in Immunology 78 1–56.


Ridker PM 2016 From C-reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection. Circulation Research 118 145–156. (doi:10.1161/CIRCRESAHA.115.306656)

Roberson AK & Hansson GK 2006 T cells in atherogenesis: for better or for worse? Arteriosclerosis, Thrombosis, and Vascular Biology 26 2421–2432. (doi:10.1161/01.ATV.0000245830.29764.84)


Uçker R, Aslan M, Atmaca M, Alay M, Ademoglu EN & Gulsen I 2015 Evaluation of blood neutrophil to lymphocyte and platelet to lymphocyte ratios according to plasma glucose status and serum insulin-like growth factor 1 levels in patients with acromegaly. *Human and Experimental Toxicology* 46 748–748. (doi:10.1203/00006450-199912000-00019)

Received in final form 16 May 2017
Accepted 13 June 2017
Accepted Preprint published online 13 June 2017